Odronextamab is a Monoclonal Antibody owned by Regeneron Pharmaceuticals, and is involved in 12 clinical trials, of which 5 are ongoing, and 7 are planned.
Odronextamab is a bi-specific monoclonal antibody binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, resulting in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.The CD-20 antigen is a non-glycosylated phosphoprotein, which is important in cell proliferation and differentiation and is found to be expressed on tumor cells.
The revenue for Odronextamab is expected to reach a total of $3.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Odronextamab NPV Report.
Odronextamab is under development for the treatment of relapsed/refractory B- cell non-Hodgkin's lymphomas including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, B-cell Hodgkin's lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia. The therapeutic candidate is administered intravenously. It is an anti-CD20 and anti-CD3 bi-specific monoclonal antibody. It is developed based on VelociSuite technology.
Zai Lab Overview
Zai Lab biopharmaceutical company that carries out drug development, discovery and commercializing therapies which address medical conditions with unmet needs in oncology. The company offering products pipeline includes Zejula Niraparib is a once-daily small molecule poly (ADP-ribose) polymerase 1/2inhibitor, Optune Tumor Treating Fields for cancer treatment, Qinlock Ripretinib and NUZYRA Omadacycline, a novel tetracycline-class antibacterial. The company market its products to the United States, Europe, Canada, Australia, Greater China and certain other countries and regions. Zai Lab is headquartered in Shanghai, China.
The company reported revenues of (US Dollars) US$144.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$49 million in FY2020. The operating loss of the company was US$700.1 million in FY2021, compared to an operating loss of US$301.8 million in FY2020. The net loss of the company was US$704.5 million in FY2021, compared to a net loss of US$268.9 million in FY2020. The company reported revenues of US$57.5 million for the third quarter ended September 2022, an increase of 19.4% over the previous quarter.
Quick View – Odronextamab
|Highest Development Stage|